ArticleBMC cardiovascular disorders2025
High-sensitivity c-reactive protein and cardiovascular disease risk assessment in a population of type 2 diabetes mellitus patients.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lipid-based atherogenic indices and their relationship with cardiovascular disease risk in an African population of type 2 diabetes mellitus patients.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Article
- Mobile-application-based performance feedback improves physical activity behaviour compared to education alone: a randomised controlled trial.BMC digital health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) remains the leading cause of mortality in individuals with type 2 diabetes mellitus (T2DM), driven by chronic hyperglycaemia, dyslipidaemia, and systemic inflammation. In Nigeria, genetic predispositions, ethnic and environmental factors may further modulate CVD risk. This study aimed to evaluate the association between high-sensitivity C-reactive protein (hsCRP) and CVD risk in Nigerian T2DM patients receiving standard care.
methodsThis cross-sectional hospital-based study was conducted over 13 months. Data on socio-demographic characteristics, medical history, clinical findings, and laboratory parameters were collected using a structured proforma. Serum hsCRP was measured by homogenous immunoassay, while 10-year CVD risk was estimated with the WHO CVD risk assessment chart validated for Western sub-Saharan Africa. Statistical analyses, including binary logistic regression to assess the association between hsCRP and CVD risk, were conducted using SPSS version 25, with significance set at p < 0.05.
resultsModerate-to-high CVD risk was prevalent in 51.5% of the study population. Longer diabetes duration (AOR = 1.345, 95% CI: 1.222-1.480, p < 0.001), elevated HbA1c (OR = 1.438, 95% CI: 1.061-1.949, p = 0.019), and co-morbid hypertension (OR = 14.498, 95% CI: 2.611-80.515, p = 0.002) were significantly associated with higher CVD risk. Serum hsCRP levels were higher in moderate-to-high-risk individuals (median: 2.42 mg/L, IQR: 2.8; 2.71 mg/L, IQR: 1.8) compared to lower-risk individuals (median: 1.22 mg/L, IQR: 2.5; 1.48 mg/L, IQR: 2.6), p = 0.012. However, it was not an independent predictor of CVD risk after adjusting for confounders (p = 0.369).
conclusionThere is a high burden of increased CVD risk in this population despite ongoing management, with prolonged diabetes duration, poor glycaemic control and co-morbid hypertension as key predictors. Although hsCRP levels were elevated in higher-risk individuals, its clinical utility as an independent predictor of CVD risk may be limited. These findings emphasize the need to strengthen routine CVD risk assessment, prioritize modifiable risk factors, and optimize glycaemic control to reduce CVD burden in Nigerian T2DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.